Clinical Trial Update: Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of imetelstat in children with refractory or recurrent solid tumors or lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• Imetelstat (imetelstat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Solid Tumors, Lymphoma | Phase 1 | Status: WITHDRAWN